VENTYX BIOSCIENCES IN

Ventyx Biosciences Appoints Allison J. Hulme, Ph.D. and Onaiza Cadoret-Manier to its Board of Directors

12 1 2023 07:00:00 提供 Nasdaq GlobeNewswire

Ventyx Biosciences to Host R&D Event on January 26, 2023

05 1 2023 07:00:01 提供 Nasdaq GlobeNewswire

Ventyx Biosciences Announces Dosing of the First Patient in the Phase 2 SERENITY Trial of VTX958 for the Treatment of Moderate to Severe Plaque Psoriasis

01 12 2022 15:05:00 提供 Nasdaq GlobeNewswire

Ventyx Biosciences to Participate in Two Upcoming Investor Conferences

22 11 2022 07:00:02 提供 Nasdaq GlobeNewswire

Ventyx Biosciences Reports Third Quarter 2022 Financial Results and Highlights Recent Corporate Progress

03 11 2022 15:01:01 提供 Nasdaq GlobeNewswire

Ventyx Biosciences to Report Third Quarter 2022 Financial Results on November 3, 2022

27 10 2022 15:05:01 提供 Nasdaq GlobeNewswire

Ventyx Biosciences to Participate in Three Upcoming Investor Conferences

27 10 2022 08:00:01 提供 Nasdaq GlobeNewswire

Ventyx Biosciences Announces $176.6 Million Private Placement of Common Stock

19 9 2022 07:00:00 提供 Nasdaq GlobeNewswire

Ventyx Biosciences to Participate in Two Upcoming Investor Conferences

29 8 2022 15:05:00 提供 Nasdaq GlobeNewswire

Ventyx Biosciences Reports Second Quarter 2022 Financial Results and Highlights Recent Corporate Progress

15 8 2022 15:05:01 提供 Nasdaq GlobeNewswire

Ventyx Biosciences Announces Positive Topline Phase 1 Data for Its Selective Allosteric TYK2 Inhibitor VTX958

15 8 2022 15:01:00 提供 Nasdaq GlobeNewswire

Ventyx Biosciences to Report Topline Results from the Phase 1 trial of its TYK 2 Inhibitor VTX958 and Second Quarter 2022 Financial Results on August 15, 2022

11 8 2022 15:05:03 提供 Nasdaq GlobeNewswire

Ventyx Biosciences Announces Positive Topline Phase 1 Data for its Peripheral NLRP3 Inhibitor VTX2735

29 6 2022 07:00:01 提供 Nasdaq GlobeNewswire

Ventyx Biosciences to Participate in the Jefferies Healthcare Conference

01 6 2022 07:00:01 提供 Nasdaq GlobeNewswire

Ventyx Biosciences Reports First Quarter 2022 Financial Results and Highlights Recent Corporate Progress

12 5 2022 15:01:00 提供 Nasdaq GlobeNewswire

Ventyx Biosciences Announces Appointment of William Sandborn, MD, as President and Chief Medical Officer

09 5 2022 07:00:01 提供 Nasdaq GlobeNewswire

Ventyx Biosciences to Report First Quarter 2022 Financial Results on May 12, 2022

05 5 2022 15:05:01 提供 Nasdaq GlobeNewswire

Ventyx Biosciences Reports Full Year 2021 Financial Results and Highlights Recent Corporate Progress

23 3 2022 07:00:01 提供 Nasdaq GlobeNewswire

Ventyx Biosciences to Participate in the Barclays Global Healthcare Conference

07 3 2022 07:00:01 提供 Nasdaq GlobeNewswire

Ventyx Biosciences Announces First Patient Dosed in a Phase 2 Clinical Trial of VTX002 for the Treatment of Moderate-to-Severe Ulcerative Colitis

06 12 2021 07:00:01 提供 Nasdaq GlobeNewswire